Q-omics provides the consensus-scored GLT8D1 profile across patient tissues and cancer cell-line models. GLT8D1 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, GLT8D1 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, GLT8D1 protein abundance shows 22,080 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UCEC, HNSC, and GBM as cancer lineages where GLT8D1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GLT8D1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GLT8D1 survival associations across molecular data types. GLT8D1 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (2) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GLT8D1 RNA expression–survival associations across cancer types. High GLT8D1 expression shows unfavorable associations in STAD, ACC, MESO and LGG, but favorable associations in UCEC and COAD. The UCEC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for GLT8D1 RNA expression.
This table summarizes GLT8D1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for GLT8D1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GLT8D1 shows lower tumor expression in THCA and KIRC and higher tumor expression in HNSC, COAD, BLCA and LIHC. The HNSC box plot shows higher GLT8D1 RNA expression in tumor versus normal tissue (log2 FC = +0.522, t-test p < 0.001).
This table shows molecular features associated with GLT8D1 in patient tissues and cancer cell lines. In patient samples, GLT8D1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, GLT8D1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and UPPER_AERODIGESTIVE_TRACT.
